Andrew Phillips's most recent trade in MoonLake Immunotherapeutics - Ordinary Shares - Class A was a trade of 6,682 Option to Buy done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutic... | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 6,682 | 6,682 | - | - | Option to Buy | |
| OnKure Therapeutics Inc. -... | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 7,650 | 7,650 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 20,491 | 20,491 | - | - | Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
| MoonLake Immunotherapeutic... | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 7,688 | 7,688 | - | - | Option to Buy | |
| Enliven Therapeutics Inc | Phillips Andrew | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 23,364 | 23,364 | - | - | Stock Option (right to buy) | |
| MoonLake Immunotherapeutic... | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 11,297 | 11,297 | - | - | Option to Buy | |
| Enliven Therapeutics Inc | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 27,567 | 27,567 | - | - | Stock Option (right to buy) | |
| MoonLake Immunotherapeutic... | Andrew Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2022 | 45,000 | 45,000 | - | - | Option to Buy |